Just How Big is the Psychedelics Opportunity?


Ryan Allway

October 27th, 2020

App, Exclusive, Psychedelics, Top Story


The North American market for psychedelic drugs is projected to reach $6.85 billion by 2027, according to Data Bridge Market Research, which represents a 16.3% compound annual growth rate. After the approval of Johnson & Johnson’s (NYSE: JNJ) SPRAVATO nasal spray for treatment-resistant depression and two Breakthrough Therapy designations, there has been an explosion of companies raising capital to revolutionize multi-billion-dollar mental health markets.

Let’s take a look at the rise of psychedelic therapies, their potential to treat massive mental health markets and why MagicMed Industries Inc. is well-positioned to capitalize on the nascent market with its unique business model.

Psychedelics Go Mainstream

Psychedelics have rapidly emerged from fringe to mainstream research and development. The Imperial College of London, University of California-Berkeley and Johns Hopkins have all established psychedelic research centers while the Food and Drug Administration (FDA) designated Breakthrough Therapy status to two psychedelics in active clinical trials.

In addition to research and development, the capital markets have shown an insatiable appetite for psychedelic opportunities. Compass Pathways Inc. (NASDAQ: CMPS) roughly doubled following its initial public offering on the NASDAQ, reaching a market capitalization of more than one billion dollars despite its development-stage efforts.

The combination of research interest and capital has created a perfect storm that could help millions of people suffering from mental health conditions and transform the market for mental health treatments. These markets are worth billions of dollars per year and are underserved by conventional pharmaceuticals and other treatment options.

Click here to learn more about investing in psychedelics

Massive Mental Health Markets

More than one-quarter of Americans over 18 suffer from a diagnosable mental health disorder in a given year and roughly 17.3 million adults have experienced at least one major depressive episode, according to Johns Hopkins. In fact, mental health disorders account for several of the top causes of disability in established economies worldwide.

Psychedelics have a unique mechanism of action that could play an important role in treating a wide range of these mental health disorders. While antidepressants and other mental health medications have been around for a long time, generating billions of dollars’ worth of sales each year, they have questionable efficacy for a majority of patients.

The biggest potential markets for psychedelics include:

Mental Health Disorder Market Size
Attention Deficit Hyperactivity Disorder $9.1 Billion
Substance Abuse Treatments $42 Billion
Generalized Anxiety Disorder $4.5 Billion
Depression $4 Billion

Beyond these markets, there are a host of medical indications that are underserved by conventional therapeutics where psychedelics could play an important role. Emerging research suggests that psychedelics provide a unique mechanism of action that differs from conventional mental health treatments, providing safer and more permanent alternatives.

How to Invest in Psychedelics

There are a growing number of public and private companies targeting the psychedelics space, ranging from Compass Pathways Inc. (NASDAQ: CMPS) to Red Light Holland Corp. (CSE: TRIP). While many of these companies are conducting clinical trials with the goal of an approved pharmaceutical, others are taking a more unique approach to the market.

MagicMed Industries aims to become a leader in the development of new psychedelic molecular derivatives. While psilocybin and other naturally occurring psychedelic molecules aren’t patentable, derivatives can be fine-tuned to meet specific goals (e.g. less psychoactive effects) and enable pharmaceuticals companies to better commercialize.

Click here to learn more about investing in psychedelics

The company is building the Psybrary™ to house a range of psychedelic molecules that it plans to license to pharmaceutical or biotechnology drug development partners. By licensing the molecules, the company plans to generate payments based on clinical milestones and ongoing royalties on any approved pharmaceutical product—creating high-margin recurring revenue.

In addition to the attractive revenue stream, shareholders have access to a diverse range of partners that provide diversified exposure to the industry. Management hopes to onboard its first partner in 2020, become cash flow positive during 2021, and potentially even diversify into consumer goods in 2022.

Looking Ahead

The psychedelics industry could disrupt multiple segments of the mental health market with billions of dollars in annual sales. While many companies are pursuing a clinical approach to the market, MagicMed Industries aims to become a leader in developing psychedelic derivative molecules that it licenses to pharmaceutical companies.

Investors may want to keep an eye on the company as its gears up to become a publicly-traded company during the first or second quarter of next year.

For more information, visit the company’s website or download their investor presentation.

MagicMed Company Contact:

Investor Relations

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading